Brokerages forecast that Supernus Pharmaceuticals Inc (NASDAQ:SUPN) will post sales of $109.26 million for the current quarter, Zacks reports. Four analysts have provided estimates for Supernus Pharmaceuticals’ earnings. The highest sales estimate is $111.45 million and the lowest is $106.20 million. Supernus Pharmaceuticals posted sales of $103.00 million in the same quarter last year, which suggests a positive year-over-year growth rate of 6.1%. The firm is scheduled to issue its next earnings report on Tuesday, November 5th.
On average, analysts expect that Supernus Pharmaceuticals will report full-year sales of $414.98 million for the current financial year, with estimates ranging from $410.90 million to $419.58 million. For the next fiscal year, analysts anticipate that the company will post sales of $451.75 million, with estimates ranging from $435.77 million to $466.80 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.05. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. The company had revenue of $104.70 million during the quarter, compared to the consensus estimate of $109.67 million. During the same period last year, the firm earned $0.57 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis.
SUPN stock opened at $26.60 on Friday. The firm has a 50 day moving average of $27.19 and a 200-day moving average of $31.10. Supernus Pharmaceuticals has a 12-month low of $24.77 and a 12-month high of $49.25. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. The company has a market cap of $1.39 billion, a price-to-earnings ratio of 12.98, a PEG ratio of 0.93 and a beta of 1.61.
In other Supernus Pharmaceuticals news, CEO Jack A. Khattar acquired 7,200 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was acquired at an average cost of $26.39 per share, with a total value of $190,008.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 6.57% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Supernus Pharmaceuticals by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 5,345,217 shares of the specialty pharmaceutical company’s stock worth $176,873,000 after purchasing an additional 49,676 shares in the last quarter. Rice Hall James & Associates LLC grew its stake in Supernus Pharmaceuticals by 35.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 1,351,286 shares of the specialty pharmaceutical company’s stock worth $44,714,000 after acquiring an additional 350,905 shares during the period. Macquarie Group Ltd. grew its stake in Supernus Pharmaceuticals by 8.5% in the 2nd quarter. Macquarie Group Ltd. now owns 1,079,001 shares of the specialty pharmaceutical company’s stock worth $35,705,000 after acquiring an additional 84,846 shares during the period. Neumeier Poma Investment Counsel LLC grew its stake in Supernus Pharmaceuticals by 1.1% in the 2nd quarter. Neumeier Poma Investment Counsel LLC now owns 957,401 shares of the specialty pharmaceutical company’s stock worth $31,680,000 after acquiring an additional 10,170 shares during the period. Finally, Provident Investment Management Inc. grew its stake in Supernus Pharmaceuticals by 13.8% in the 2nd quarter. Provident Investment Management Inc. now owns 726,333 shares of the specialty pharmaceutical company’s stock worth $24,034,000 after acquiring an additional 88,099 shares during the period. 99.14% of the stock is owned by institutional investors and hedge funds.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
See Also: Trading Ex-Dividend Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.